

REMARKS/ARGUMENTS

Reconsideration of this patent application is respectfully requested in view of the foregoing amendments, and the following remarks. Claims 1-22 and 25-34 are in the application. Claim 1 has been amended. No new matter has been added.


The Examiner rejected claims 1-22 and 25-34 under 35 U.S.C. §112, first paragraph, for being non-enabled. The Examiner states that the claimed method recites sequential measurement of only fluorescence emissions associated with large numbers of cells stained with each of the combinations of monoclonal antibodies from the normal/reactive samples and neoplastic sample, without any limitation as to the number of fluorescence emissions measurements performed for each cell. The Examiner also states that the specification only enables measuring at least two light scatter emissions and at least four fluorescence emissions for each stained cell, as described on page 13 of the specification.

Applicants have amended step b) of claim 1 to recite that at least two light scatter emissions and at least four fluorescence emissions are measured for each stained cell, as is described on

page 13 of the specification.

Accordingly, Applicants submit that the amended claims are in compliance with 35 U.S.C. §112. Early allowance is respectfully requested.


Respectfully submitted,
Alberto Orfao DE MATOS CORREIA E VALLE ET AL



COLLARD & ROE, P.C.
1077 Northern Boulevard
Roslyn, New York 11576
(516) 365-9802
ECR:pk

Elizabeth C Richter, Reg. No. 35,103
Frederick J. Dorchak, Reg. No. 29,298
Attorneys for Applicants

I hereby certify that this correspondence is being filed electronically in the United States Patent and Trademark Office on November 11, 2008.


Elizabeth C. Richter